National Protocol for Model-Based Selection for Proton Therapy in Head and Neck Cancer

Johannes A. Langendijk, MD, PhD; Frank J. P. Hoebers, MD, PhD; Martin A. de Jong, MD; Patricia Doornaert, MD, PhD; Chris H. J. Terhaard, MD, PhD; Roel J. H. M. Steenbakkers, MD, PhD; Olga Hamming-Vrieze, MD, PhD; Jeroen B. van de Kamer, PhD; Wilko F. A. R. Verbakel, PhD; Fatma Keskin-Cambay, MD; Johannes B. Reitsma, MD, PhD; Arjen van der Schaaf, PhD; Liesbeth J. Boersma, MD, PhD; Ewoud Schuit, PhD

1Department of Radiation Oncology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands
2Department of Radiation Oncology (MAASTRO clinic), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, the Netherlands
3Department of Radiation Oncology, Leiden University Medical Centre, Leiden, the Netherlands
4Department of Radiation Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands
5Department of Radiation Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands
6Department of Radiation Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, the Netherlands
7Department of Radiation Oncology, Erasmus Medical Center, Rotterdam, the Netherlands
8Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

Abstract

In the Netherlands, the model-based approach is used to identify patients with head and neck cancer who may benefit most from proton therapy in terms of prevention of late radiation-induced side effects in comparison with photon therapy. To this purpose, a National Indication Protocol Proton therapy for Head and Neck Cancer patients (NIPP-HNC) was developed, which has been approved by the health care authorities. When patients qualify according to the guidelines of the NIPP-HNC, proton therapy is fully reimbursed. This article describes the procedures that were followed to develop this NIPP-HNC and provides all necessary information to introduce model-based selection for patients with head and neck cancer into routine clinical practice.

Keywords: head and neck cancer; proton therapy; model-based selection; national indication protocol; radiation-induced side effects

Introduction

Radiation therapy in head and neck cancer (HNC) may result in a variety of acute and late radiation-induced toxicities significantly affecting quality of life (QoL) [1]. In the last decades, new photon-based radiation techniques, like 3-dimensional conformal radiation therapy (3DCRT) and intensity-modulated radiation therapy (IMRT), have been introduced to minimize radiation exposure to nontarget normal tissues to prevent radiation-induced toxicities. Owing to the superior beam properties of protons, radiation exposure to normal tissues can be further reduced, especially when using pencil beam scanning intensity-modulated proton therapy (IMPT) [2].
In the Netherlands, HNC patients qualify for proton therapy (PT) through the model-based approach [3, 4]. In summary, for all patients who may benefit from PT, a comparison is made between the most optimal photon and proton treatment plans. Then, normal tissue complication probability (NTCP) profiles, that is, expected toxicity rates, are estimated for both techniques. These NTCP profiles include dose distribution parameters in the organs-at-risk (OARs) and other clinical or treatment variables most relevant for the development of radiation-induced side effects. Finally, the expected clinical benefit in terms of toxicity reduction by using protons instead of photons can be calculated by subtracting the photon-based from the proton-based NTCP profile ($\Delta$NTCP profile).

To guide model-based selection, a National Indication Protocol for PT for HNC patients (NIPP-HNC) was developed, including a detailed description of the NTCP models used for model-based selection. This article describes how the NIPP-HNC was developed and provides all information required to enable model-based selection in routine clinical practice.

### Materials and Methods

#### NIPP-HNC Development Procedure

##### Working group

The NIPP-HNC was the first protocol for model-based selection for PT in the Netherlands. This section describes the procedure followed to arrive at the final version of the NIPP-HNC. A working group (WG) was formed composed of experts in the field of PT and in the field of HNC radiation therapy, with representatives from proton centers as well as centers without a formal relationship with a proton center. A clinical epidemiologist (E.S.) with special expertise in the field of clinical prediction modeling was added to the WG.

##### NTCP model selection

The first task of the WG was to select NTCP models most suitable for model-based selection. A literature search was conducted to identify papers reporting on NTCP models for radiation-induced toxicity after head and neck radiation therapy. All abstracts were reviewed by at least 2 group members and then discussed in a plenary session in which all members participated.

All papers were reviewed by using a checklist with 7 basic quality criteria as described in more detail in a previous report [3]. In addition, each model was assigned a stage of evaluation according to the TRIPOD criteria (Table 1) [5]. From these quality criteria, the WG assigned which NTCP models were considered most suitable for model-based selection. After selecting the most suitable NTCP models, an external validation and if necessary model update was performed on available original datasets.

For this first version of the NIPP-HNC, we decided to focus only on xerostomia and dysphagia as these are the most prevalent late radiation-induced toxicities in HNC patients and as they have a significant impact on the general dimensions of QoL [1].

| Level | Description |
|-------|-------------|
| 1a    | External validation in separate dataset using new technology in another center |
| 1b    | External validation in separate dataset using new technology in same center or same technology in another center |
| 2a    | External validation in separate dataset using nonrandom split in test and validation set |
| 2b    | External validation in separate dataset using random split in test and validation set |
| 3     | Development and internal validation |
| 4a    | Multivariable NTCP model without internal or external validation |
| Level 4b | Univariable NTCP model without internal or external validation |

Abbreviation: NTCP, Normal Tissue Complication Probability.
**Thresholds for ΔNTCP**

To arrive at a transparent and uniform system for deciding which patients will be candidates for PT, specific thresholds for ΔNTCP for the relevant toxicity outcomes needed to be agreed upon. These thresholds were established in July 2016 by the general assembly of the Netherlands Society of Radiation Oncology (NVRO) and are based on the toxicity grading according to the Common Toxicity Criteria for Adverse Events version 4.0 (CTCAE4.0) [2, 3]. In summary, grade 1 toxicities include clinical or diagnostic observations that are asymptomatic or only lead to mild symptoms and as such were not considered relevant in model-based selection. For grade ≥ II, grade ≥ III, and grade ≥ IV toxicities, the minimal thresholds for ΔNTCP were set on 10%, 15%, and 20%, respectively, reflecting the increasing impact on age-appropriate instrumental activities of daily living (ADL), self-care ADL, and QoL. In case 2 or more NTCP models are used in the NIPP-HNC, patients also qualify for PT if the sum of 2 ΔNTCP values of the same toxicity grade (eg, grade ≥ II xerostomia and grade ≥ II dysphagia) are ≥15%, ≥7.5%, and ≥3%, respectively. No summation is performed across different grades. These summation thresholds were arbitrarily chosen and approved by the general assembly of the NVRO, considering the prevalence of side effects and the impact they have on patients’ functioning and QoL.

The decision to use the CTCAE4.0 as a basis for model-based selection has some drawbacks. First, as the CTCAE4.0 is relatively new, the number of NTCP models based on this classification system will be limited. When using NTCP models for other endpoints (eg, patient-rated), the endpoint definitions should be translated to the definition of the CTCAE4.0 as closely as possible, and a detailed description should be provided in a conversion table.

**Procedure to approve the NIPP-HNC**

Based on the literature review and additional external validation of selected models (next paragraph), a first concept NIPP-HNC was written by the NIPP-WG that was then distributed among the members of the National Platform for Proton Therapy (LPPT) and the National Platform for Head and Neck Radiotherapy (LPRHHT) for review and comments. The LPRHHT includes representatives of all radiation therapy departments in the Netherlands that treat HNC patients and is mandated to decide on site-specific guidelines for head and neck radiation therapy.

Based on the comments of the LPPT and LPRHHT, a second concept was distributed across other relevant stakeholders, such as patient advocacy groups, health insurance companies, and other relevant groups like the Dutch Society for Head and Neck Tumors and discussed during an invitational conference with these stakeholders. Based on the comments of the participants of the invitational conference, the final version was submitted to the LPRHHT for definitive approval.

The final version of the NIPP-HNC was then submitted to the National Health Care Institute (Zorginstituut Nederland, Diemen, The Netherlands). This Institute is the formal advisory organization for the Health Insurance Act. New medical interventions can only be included in the basic health care insurance package when the National Health Care Institute concludes that the scientific evidence showing a clinically relevant beneficial effect is sufficient. In October 2017, the NIPP-HNC was formally approved. Consequently, when HNC patients qualify for PT according to the guidelines of the NIPP-HNC, PT is fully reimbursed. The first patients were selected according to the guidelines of the NIPP-HNC in January 2018 and were subsequently treated with PT.

**NTCP Model Selection**

**Xerostomia**

The literature search did not reveal any useful studies on models for physician-rated xerostomia according to the CTCAE. Two studies were found describing the relationship between the mean parotid dose and LENT-SOMA (Late Effects Normal Tissues – Subjective, Objective, Management, Analytic) grade ≥ 2 and RTOG (Radiation Therapy Oncology Group) grade ≥ 3 xerostomia but the quality of these studies was regarded insufficient for either model-based selection or external validation [6, 7]. However, 7 studies were found reporting on the relationship between dose and patient-rated moderate-to-severe dry mouth as an endpoint at 3, 6, and/or 12 months after treatment (Table 2), using the EORTC QLQ-H&N35 (European Organization for Research and Treatment Quality of Life Questionnaire Head and Neck 35) [8–14]. In most studies, moderate-to-severe dry mouth was classified as a grade 3 complication, but according to the definitions of the CTCAE4.0, this endpoint is more consistent with grade 2 (ie, moderate symptoms). From the literature review, the NIPP-WG selected the model published by Beetz et al [8] for further external validation and revision. The main reasons to select this NTCP model was as follows: (1) treatment of patients with modern radiation techniques (IMRT); (2)
meticulous prospective assessment of patient-rated xerostomia with high compliance rates; (3) reasonable number of patients and events; (4) use of multivariable analysis with internal validation by means of bootstrapping; (5) good model performance; and (6) original datasets available to enable model validation and revision.

Dysphagia

Based on the qualitative criteria (Table 3), the NTCP model published by Christianen et al [15] was ranked highest for the same reasons mentioned of xerostomia. Another advantage was that the definition of the OARs involved in swallowing was described in detail in a separate article, increasing consistency of OAR delineation and reproducibility [20]. Moreover, a prospective cohort study demonstrated that swallowing-sparing IMRT using the dose parameters of this model for dose optimization actually reduced the prevalence of dysphagia grade II [16]. Another study found that this NTCP model proved to be a good predictor of the risk of dysphagia grade II after PT as well [17].

Tube feeding dependence

In 5 studies the relationship between dose distributions in OARs and tube feeding dependence was described (Table 4) [21–25]. The endpoint in these studies was tube feeding dependence during radiation therapy, and at 6 to 12 months and beyond 12 months after completion of radiation therapy. This endpoint occurs when a patient is no longer able to maintain nutritional status without a nasal tube or percutaneous endoscopic gastrostomy tube. This endpoint corresponds to grade III (“dysphagia”) according to the CTCAEv4.0. From the evaluation of the NIPP-WG, the NTCP model published by Wopken et al [23] was selected for further external validation for the same reasons as mentioned for xerostomia.

| Reference | Time point, mo | RT technique | Study design | Analysis | No. of patients | No. of events | AUC | Calibration tested | Internal validation | External validation | NTCP estimation possible | Level of evidence |
|-----------|----------------|--------------|--------------|----------|----------------|---------------|-----|--------------------|---------------------|---------------------|----------------------|-----------------|
| Current study | 6 | Prim IMRT | Prospective | External validation | 669 | 338 | 0.72 | Yes | Yes | Yes | Yes | Yes | 2a |
| Beetz 2012a [10] | 6 | Prim 3DCRT | Prospective | Multivariable | 165 | 86 | 0.82 | No | Yes | No | Yes | 3 |
| Beetz 2012b [9] | 6 | Prim IMRT | Prospective | External validation | 161 | 83 | 0.66 | Yes, poorb | Yes | Poor | Yes | 3 |
| Beetz 2012c [8] | 6 | Prim IMRT | Prospective | Multivariable | 161 | 83 | 0.69 | Yes | Yes | No | Yes | 3 |
| Lee 2012 [11] | 12 | Prim + PO IMRT | Prospective | Univariable | 31 | NM | 0.75 | Yes | No | No | Yes | 4 |
| Lee 2013 [12] | 3 | Prim + PO IMRT | Prospective | LKB-model | 237 | 89 | 0.68 | No | No | No | Yes | 4 |
| | 12 | | | | 146 | 49 | 0.73 | No | No | No | Yes | 4 |
| Lee 2014 [13] | 3 | Prim + PO IMRT | Prospective | Multivariable | 185 | 87 | 0.86 | No | Yes | No | Yes | 3 |
| | 12 | | | | 117 | 43 | 0.86 | No | Yes | No | Yes | 3 |
| Jellema 2005 [14] | 6 | Prim + PO 3DCRT | Prospective | Multivariable | 113 | 46 | 0 | No | No | No | No | Yes | 4 |
| | 12 | | | | 94 | 35 | | | No | No | No | No | 4 |

Abbreviations: NTCP, Normal Tissue Complication Probability; EORTC QLQ-H&N35, European Organization for Research and Treatment Quality of Life Questionnaire Head and Neck 35; RT, radiation therapy; AUC, Area Under the Curve.; Prim, primary; IMRT, intensity-modulated radiation therapy; 3DCRT, 3-dimensional conformal radiation therapy; PO, postoperative; LKB, Lyman-Kutcher-Burman model.

*The NTCP model of Beetz 2012c [8] was ranked highest and subjected to external validation as described in this article.

bThis study tried to validate the model of Beetz 2012a [10], developed in patients treated with 3DCRT, in a patient population treated with IMRT. This model performed poorly in the IMRT population, especially regarding calibration.
### Table 3. Overview of studies on NTCP models for dysphagia grade II-IV according to the RTOG/EORTC Late Radiation Toxicity Scoring system.

| Reference       | Time point, mo | RT technique       | Study design | Analysis       | No. of patients | No. of events | AUC  | Calibration tested | Internal validation | External validation | Individual NTCP estimation possible | Level of evidence |
|-----------------|----------------|--------------------|--------------|----------------|-----------------|---------------|------|--------------------|---------------------|---------------------|-------------------------------|------------------|
| Current study   | 6              | Primary IMRT       | Prospective  | External validation | 813             | 242           | 0.81 | Yes                | Yes                 | Yes                 | Yes                           | 1b               |
| Christianen 2012 [15] | 6              | Primary 3DCRT and IMRT | Prospective  | Multivariable    | 354             | NM            | 0.80 | No                 | Yes                 | No                  | Yes                           | 3               |
| Christianen 2016 [16]a | 6              | SW-IMRT            | Prospective  | External validation | 186             | 59            | 0.75 | Yes                | No                  | Yes                 | Yes                           | 2a               |
| Blanchard 2016 [17]b | 6              | Protons            | Prospective  | External validation | 89              | 27            | 0.70 | Yes                | Yes                 | Yes                 | Yes                           | 1a               |
| Dirix 2009 [18]  | Variable       | Primary IMRT       | Cross-sectional | Multivariable   | 53              | 14            | NM      | No                  | No                  | No                  | No                           | 4               |
| Mazzola 2014 [19] | Acute          | Primary IMRT       | Retrospective | Univariable     | 53              | 46            | NM      | No                  | No                  | No                  | No                           | 4               |
| Late            |                |                    |              |                 | 13              | 12            | NM      | No                  | No                  | No                  | No                           | 4               |

**Abbreviations:** NTCP, Normal Tissue Complication Probability; RTOG/EORTC, Radiation Therapy Oncology Group / European Organization for Research and Treatment; RT, radiation therapy; AUC, Area Under the Curve; 3DCRT, 3-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; NM, Not mentioned; SW-IMRT, swallowing-sparing IMRT; DVH, dose-volume histogram.

*aThis study used the NTCP model from Christianen 2012 [15] to guide treatment planning optimization using the DVH parameters of the NTCP model. The study showed that the observed toxicity rates were lower with SW-IMRT and that the observed toxicity rates corresponded very well with the predicted rates based on the NTCP model.

*bThis study externally validated the NTCP model from Christianen 2012 [15] among patients treated with protons.

### Table 4. Overview of studies on NTCP models for tube feeding dependence.

| Reference       | Time point, mo | RT technique     | Study design | Analysis       | No. of patients | No. of events | AUC  | Calibration tested | Internal validation | External validation | Individual NTCP estimation possible | Level of evidence |
|-----------------|----------------|------------------|--------------|----------------|-----------------|---------------|------|--------------------|---------------------|---------------------|-------------------------------|------------------|
| Current study   | 6              | Primary IMRT     | Prospective  | External validation | 867             | 102           | 0.87 | Yes                | Yes                 | Yes                 | Yes                           | 1b               |
| Caudell 2010 [21] | 12             | IMRT             | Retrospective | Univariable    | 83              | 18            | -    | No                  | No                  | No                  | No                           | 4               |
| Sanguineti 2011 [22] | During RT IMRT | Retrospective | Multivariable |               | 59              | 22            | -    | No                  | No                  | Yes                 | Yes                           | 4               |
| Wopken 2014 [23] | 6              | Primary 3DCRT and IMRT | Prospective  | Multivariable   | 355             | 38            | 0.88 | Yes                | Yes                 | No                  | Yes                           | 3               |
| Vlacich 2014 [24] | >12            | IMRT             | Retrospective | Univariable    | 141             | 18            | -    | No                  | No                  | No                  | No                           | 4               |
| LI 2009 [25]    | >6             | IMRT             | Retrospective | Univariable    | 39              | -             | -    | No                  | No                  | No                  | No                           | 4               |

**Abbreviations:** NTCP, Normal Tissue Complication Probability; RT, radiation therapy; AUC, Area Under the Curve; 3DCRT, 3-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy.
External Validation and Revision of Selected Models

**Patients**

Patients were eligible for external validation in case of the following inclusion criteria: squamous cell HNC; primary tumor site in oral cavity, pharynx, and larynx; stage I-IV but M0; definitive radiation therapy with or without concomitant chemotherapy or cetuximab; treatment with IMRT or VMAT; minimal follow-up of 6 months after radiation therapy; and no previous HNC treatment. Patients had to be treated with curative intention. All NTCP models selected for external validation were previously developed at the University Medical Center Groningen. For external validation, only datasets from that center were available. Patients used for external validation were not included in previous model development studies.

All patients in the development and validation set were consecutively included in a data registration program with prospective assessment of patient, treatment, and tumor characteristics, as well as physician-rated acute and late toxicity and patient-reported outcome measures (PROMs) by means of the EORTC QLQ-C30 (European Organization for Research and Treatment Quality of Life Questionnaire C30) and EORTC QLQ-H&N35. Toxicity and PROMs were assessed at baseline, weekly during treatment, and at 6 weeks and 6 months after radiation therapy. All patients in the external validation sets were treated with photons according to the Dutch national guidelines, as described in previous reports [8, 15, 23].

**Statistical analysis**

External validation for all selected models was done retrospectively from prospectively collected data, using the close testing procedure as a basis for adjustment of the original models [26]. To account for missing values, multiple imputation was performed. For a full and more detailed description of the statistical procedure, refer to Supplemental Data S1.

**Moderate-to-severe xerostomia**

For a detailed description of the analysis for xerostomia, refer to Supplemental Data S2. This endpoint was defined as moderate-to-severe xerostomia (score 3 or 4 of question 41: “Have you had a dry mouth?” of the EORTC QLQ-H&N35) at 6 months after completion of treatment.

Patient characteristics of the development and validation cohorts are listed in Supplemental Table S2a. In contrast to the development population of the original model, the validation population included also patients with moderate or severe xerostomia at baseline. The original model included 2 predictors: the Dmean to the contralateral parotid gland and minor versus no xerostomia at baseline (XERbaseline) (Supplemental Table S2b) [8].

In summary, the analysis showed that the model required model revision, meaning that the intercept and the regression coefficients of the original model had to be adjusted as shown in Supplemental Table S2b. Considering the relevance of xerostomia at baseline for future occurrence of xerostomia, moderate-to-severe xerostomia was added as an additional category to the XERbaseline predictor.

After the external validation procedure, the NTCP value for each plan and each individual patient can be calculated by the following regression formula (RF1):

\[
\text{NTCP XER}_{\text{M6}} = \left( 1 + e^{\frac{-1.507 + 0.052 \times D_{\text{mean}} \text{ contralateral parotid gland} + 0.525 \times \text{ minor XER}_{\text{baseline}} + 1.482 \times \text{ moderate-to-severe XER}_{\text{baseline}}}}{-1} \right),
\]

where \( LP = -1.507 + 0.052 \times D_{\text{mean}} \text{ contralateral parotid gland} + 0.525 \times \text{ minor XER}_{\text{baseline}} \) (1 if \( \text{XER}_{\text{baseline}} \) is minor, 0 if not) + 1.482 \times \text{ moderate-to-severe XER}_{\text{baseline}} \) (1 if \( \text{XER}_{\text{baseline}} \) is moderate or severe, 0 if not).

**Dysphagia**

For a detailed description of the analysis of dysphagia, refer to Supplemental Data S3. Dysphagia was defined as grade II-IV dysphagia (ie, only able to eat soft or pureed food or worse) at 6 months after completion of radiation therapy (DYSPH\textsubscript{M6}) as assessed by health care providers.

The original model consisted of 2 prognostic factors: the Dmean to the superior pharyngeal constrictor muscle (PCM) and the Dmean to the supraglottic larynx (Supplemental Table S3b) [15].

The external validation set consisted of patients who had been subjected to model-based optimization, based on the original model of Christianen et al [16], and as such were different from the patients used for model development. Consequently, the Dmean of the superior PCM and the supraglottic area were significantly lower in the validation set than in the
development set. The analysis indicated that the effect of the $D_{\text{mean}}$ to the superior PCM increased, while the effect of $D_{\text{mean}}$ to the supraglottic larynx decreased to almost zero, indicating that this dose parameter had no predictive value for the risk of DYSPHM$_{M6}$ in the validation cohort. Based on more recent studies showing that other predictors like the oral cavity may be an important OAR to consider, it was decided to extend the model with other predictors (Supplemental Data S3) [27–29]. Since the original model was developed on a small set of patients and now that more data were available to allow more reliable assessment of predictor-outcome associations, we decided to redevelop the model in a larger dataset that combined the development and validation set. This resulted in a revised model for DYSPHM$_{M6}$.

The NTCP value for each plan and each individual patient can be calculated by the following regression formula (RF2):

$$\text{NTCP} \text{DYSPHM}_M = \left(1 + e^{-LP}\right)^{-1},$$

where $LP = -3.303 + D_{\text{mean}}$ oral cavity $\times 0.024 + D_{\text{mean}}$ superior PCM $\times 0.024 + \text{baseline dysphagia} \times 0.967$ (1 if baseline dysphagia is grade $\geq 2$, 0 if not).

**Tube feeding dependence**

For a detailed description of analysis of tube feeding dependence, refer to Supplemental Data S4.

Tube feeding dependence was defined as not being able to maintain adequate oral intake requiring tube feeding either by nasogastric tube feeding or percutaneous endoscopic gastrostomy at 6 months after completion of treatment (TUBEM$_{M6}$).

The original model consisted of 7 prognostics factors (Supplemental Table S4b). The closed testing procedure revealed that model revision was required. No additional predictors were added to the model [23].

The NTCP value for each plan and each individual patient can be calculated by the following regression formula (RF3):

$$\text{NTCP} \text{TUBEM}_6 = \left(1 + e^{-LP}\right)^{-1},$$

where $LP = -6.849 + 0.680 \times \text{advanced T-stage} \ (1$ if $T$ or $T4$, 0 if not) $+ 0.317 \times \text{moderate weight loss} \ (1$ if $1–10\%$, 0 if not) $+ 1.178 \times \text{severe weight loss} \ (1$ if $>10\%$, 0 if not) $+ 0.198 \times \text{accelerated radiotherapy} \ (1$ if accelerated RT, 0 if not) $+ 1.101 \times \text{chemoradiation} \ (1$ if chemoradiation, 0 if not) $+ 1.716 \times \text{radiotherapy plus cetuximab} \ (1$ if RT and cetuximab, 0 if not) $+ 0.030 \times D_{\text{mean}}$ PCM superior $+ 0.013 \times D_{\text{mean}}$ PCM inferior $+ 0.022 \times D_{\text{mean}}$ contralateral parotid $\times 0.022 + 0.008 \times D_{\text{mean}}$ cricopharyngeal muscle $\times 0.008$.

**Guidelines for Model-Based Selection in the NIPP**

The general eligibility criteria to qualify for PT include (1) primary tumor originating in the pharynx, larynx, or oral cavity; (2) no distant metastases; and (3) treatment with curative intent.

Based on the literature search and the subsequent external validation and model adjustment, the 3 revised NTCP models for xerostomia, dysphagia, and tube feeding dependence can be used for model-based selection. The regression formulas (RF1, RF2, and RF3) can be used to calculate the corresponding NTCP values for each individual patient.

The first step in model-based selection is to produce a photon plan with the most favorable NTCP values for the 3 toxicity endpoints (NTCP-profile-PHOTONS) while preserving conventional target coverage criteria and respecting conventional sparing of normal tissues. To this purpose, the dose-volume histogram (DVH) parameters of the 3 NTCP models can be used to guide treatment plan optimization, which is referred to as model-based plan optimization. Based on this photon plan, the NTCP-profile-PHOTONS can be calculated by using equations RF1, RF2, and RF3, respectively. From a practical point of view, it should be noted that a plan comparison is only meaningful if the minimal thresholds for $\Delta$NTCP can potentially be reached when the dose to normal tissues is decreased to 0 Gy by using protons. So, for each toxicity endpoint, the potential maximum $\Delta$NTCP ($\Delta$NTCP$_{\text{max}}$) has to be calculated first by the following equation:

$$\Delta\text{NTCP}_{\text{max}} = |\text{NTCP} – \text{PHOTONS}| – |\text{NTCP}_{\text{min}} – \text{PROTONS}|,$$

in which, $\text{NTCP}_{\text{min}} – \text{PROTONS}$ is the NTCP value, assuming that with protons, the dose to all DVH parameters in the model can be reduced to zero.
To determine if a plan comparison is indicated and if patients eventually qualify for PT, refer to the flowchart presented in the Figure.

**Discussion**

This article describes the procedures followed for the development of a national indication protocol for PT for HNC patients (NIPP-HNC) treated with definitive radiation therapy, with or without concurrent chemoradiation or cetuximab. The National Health Care Institute concluded that the quality of the NTCP models was sufficient for model-based selection. Consequently, when patients qualify for PT according to the guidelines of this protocol, PT is fully reimbursed.

Langendijk et al (2021), *Int J Particle Ther*
All 3 NTCP models selected for the NIPP-HNC originated from the same center, as the literature review revealed that the models developed by this center met the quality criteria most adequately. Unfortunately, at that time no other datasets were available for external validation. Further external validation of the models in additional validation populations will help to further assess the models’ external validity.

In the development and validation cohorts, patients with moderate-to-severe XER\textsubscript{\text{baseline}} were excluded. Additional analysis showed that these patients did not all classify as responders at 6 months after radiation therapy and that the average D\text{mean} to the contralateral parotid gland among responders was significantly higher than that in the nonresponders. Therefore, these patients were added to the combined dataset, increasing model precision and offering the possibility to extend clinical application to all patients treated with definitive radiation therapy. Only the D\text{mean} of the contralateral parotid gland was identified as predictor for patient-rated xerostomia. Theoretically, it could be that these dose parameters are indeed most important for the development of patient-rated xerostomia. However, this could also be due to the problem of multicollinearity resulting from the high correlation with the D\text{mean} to other salivary glands [29].

Recently, Christianen et al [16] reported on the results obtained from a subsequent cohort of 187 patients treated with swallowing-sparing IMRT, in which the D\text{mean} to the superior PCM and supraglottic larynx was minimized without jeopardizing the dose to other OARs and the target volumes. That study showed good model performance in terms of discrimination and calibration, and the observed rate of DYSPH\text{M6} corresponded very well with the predicted NTCP, indicating that minimizing the dose to these OARs indeed resulted in lower rates of DYSPH\text{M6}. Similar results were found in the current analysis with comparable discrimination and calibration. However, when the impact of the 2 dose-volume parameters were analyzed in more detail, the effect of the superior PCM was larger, but the effect of the supraglottic larynx dropped to almost zero. Consequently, the validated NTCP model would consist of only 1 dose-volume parameter of a relatively small OAR. Using such a model for dose optimization would bear the risk of pushing the dose to other anatomic sites, such as the oral cavity, while other studies indicated that the oral cavity should be considered a significant OAR, not only for dysphagia, but also for other radiation-induced side effects [18, 30–35]. It should be noted that the oral cavity was not considered when the original model was developed [2].

In the analysis of the combined cohort, the importance of the oral cavity dose as risk factor for DYSPH\text{M6} was confirmed. We found a very high correlation between the superior PCM dose and oral cavity dose, which may cause multicollinearity. There are several remedies for multicollinearity, such as deleting one of the highly correlating variables. Although this would not affect the predictive power of the model, this solution was considered not optimal as the model is intended to be used for treatment optimization as well and consequently, the dose could then be pushed into the superior PCM when the oral cavity was selected and vice versa. Another remedy for multicollinearity is to combine the 2 variables into 1 merged variable, which was considered a better solution given the intended clinical utility.

In this analysis, baseline dysphagia was also identified as an independent strong predictor of DYSPH\text{M6}. In previous publications, patients with baseline grade \( \geq 2 \) dysphagia were excluded. In this study, we decided not to exclude these patients, as additional analysis showed that a relatively large proportion of patients recovered at 6 months, and because recovery was highly dependent on the dose to the swallowing OARs. Moreover, the addition of baseline dysphagia to the NTCP model significantly improved model performance.

The original NTCP model, as reported by Wopken et al [23], performed reasonably in this subsequent independent validation cohort [15]. However, the closed testing procedure indicated that intercept adjustment and preferably model revision was required, which was confirmed by the fact that refitting the model in the validation cohort resulted in substantially different regression coefficients for some of the predictors in the model. This may be well explained by the fact that the number of patients with events in both cohorts was relatively low in relation to the number of predictors in the model, which may have resulted in overfitting of the original model as well as in the refitted model in the validation cohort.

This first version of the NIPP has some limitations. First, the regression coefficients of the predictors in the NTCP models used for model-based selection have some uncertainties, for instance because they are based on photon-based radiation techniques. Possibly, these models need further revision when used for patients treated with protons but also when used for photons with other optimization strategies. Consequently, NTCP models estimating the NTCP values for photon plans may differ from those for proton plans. Therefore, all patients treated with PT in the Netherlands are included in a prospective data registration program as described previously [8, 15, 23]. This so-called rapid-learning health care system enables continuous monitoring of the results obtained with PT and will serve as a screening tool to decide whether model revision is required or not. The data collected in ProTRAIT will also be used to externally validate the photon-based NTCP models that are currently used in the NIPP-HNC in patients treated with photons as well as protons and will be used to validate the clinical benefit of PT.
in terms of toxicity reduction according to the model-based clinical evaluation methodology [3]. A sample size calculation revealed that approximately 400 patients are required to confirm the estimated toxicity reduction with PT versus photon therapy. Given the current number of HNC patients treated with PT in the Netherlands, we expect that the first results of such a study will be available in 2022.

Second, it should be noted that all 3 endpoints concerned the assessments at 6 months after completion of treatment, as the NTCP models for these endpoints were considered most suitable for model-based selection. It could be argued that these endpoints do not reflect the toxicity severity at later time points, as they may recover at least partly over time, and thus the benefit of PT over photon therapy in the long term may be overestimated. In this regard, it should be noted that recovery of toxicity over time may occur both after proton and photon therapy and thus not necessarily affect ΔNTCP at subsequent time points. Moreover, the advantage of taking the 6-months assessment as primary endpoint is that model evaluation and revision can be performed rather quickly and results in a more dynamic rapid learning health care system.

Third, only 3 endpoints for model-based selection are used, while radiation therapy may result in a much wider range of acute and late toxicities that are not considered. Therefore, we are working on the development of comprehensive individualized toxicity risk (CITOR) profiles for HNC patients treated with radiation therapy. These CITOR profiles provide a much wider range of NTCP models for numerous acute and late toxicity endpoints during the course of radiation as well as at different time points after radiation therapy. As such, CITOR profiles may be used to produce ΔCITOR profiles, which can be regarded as biomarkers for the expected benefit of PT in terms of prevention of radiation-induced toxicity. In this regard, the current NIPP-HNC should be considered as the very first version of a dynamic document that will require further revisions in the near future.

Recently, Tambas et al [2] reported on the first experience of model-based selection in HNC. In that study, a plan comparison was made in 141 of 227 (62%) HNC patients referred for definitive radiation therapy; and using the selection procedure as described in this article, 80 patients (35%) eventually qualified for PT. Patients with advanced disease, pharyngeal tumors, and baseline complaints more frequently qualified for PT. They showed significant reductions in all DVH parameters included in the models used for model-based selection [2]. These results illustrate that model-based selection identifies patients for which the dose to relevant OARs and associated toxicity in healthy tissue can be reduced most, and as such identifies those patients who are expected to benefit most from proton compared to photon therapy.

In conclusion, this article describes the procedure followed to create the first NIPP for model-based selection for PT for HNC patients. The results presented in this article can also be used to select patients for PT in routine clinical practice.

ADDITIONAL INFORMATION AND DECLARATIONS

Conflicts of Interest: J. A. Langendijk is Member of the International Scientific Advisory Committees of IBA and RaySearch; consultant for IBA, honorarium paid to UMCG Research BV. The department of Radiation Oncology has Research Agreement/Grant Support from Siemens, IBA, Elekta, Leonie, RaySearch, and Mirada.

Acknowledgment: Ewoud Schuit, PhD, clinical epidemiologist, is responsible for statistics.

References
1. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008;26:3770–6.
2. Tambas M, Steenbakkers RJHM, van der Laan HP, Wolters AM, Kierkels RGJ, Scandurra D, Korevaar EW, Oldehinkel E, van Zon-Meijer TWH, Both S, van den Hoek JGM, Langendijk JA. First experience with model-based selection of head and neck cancer patients for proton therapy. Radiother Oncol. 2020;151:206–13.
3. Langendijk JA, Boersma LJ, Rasch CRN, van Vulpen M, Reitsma JB, van der Schaat A, Schuit E. Clinical trial strategies to compare protons with photons. Semin Radiat Oncol. 2018;28:79–87.
4. Langendijk JA, Lambin P, De Ruyscher D, Widder J, Bos M, Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013;107:267–73.
5. Collins GS, Reitsma JB, Altmann DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162:55–63.
6. Buettner F, Miah AB, Gulliford SL, Hall E, Harrington KJ, Webb S, Partridge M, Nutting CM. Novel approaches to improve the therapeutic index of head and neck radiotherapy: an analysis of data from the PARSPORT randomised phase III trial. *Radiother Oncol*. 2012;103:82–7.

7. Marzi S, Iaccarino G, Pasciuti K, Soriani A, Benassi M, Arcangeli G, Giovinazzo G, Benassi M, Marucci L. Analysis of salivary flow and dose-volume modeling of complication incidence in patients with head-and-neck cancer receiving intensity-modulated radiotherapy. *Int J Radiat Oncol Biol Phys*. 2009;73:1252–9.

8. Beetz I, Schilstra C, van der Schaaf A, van den Heuvel ER, Doornaert P, van Luijk P, Vissink A, van der Laan BF, Leemans CR, Bijl HP, Christianen ME, Steenbakkers RJ, Langendijk JA. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors. *Radiother Oncol*. 2012;105:101–6.

9. Beetz I, Schilstra C, van Luijk P, Christianen ME, Doornaert P, Bijl HP, Chouvalova O, van den Heuvel ER, Steenbakkers RJ, Langendijk JA. Externnal validation of three dimensional conformal radiotherapy based NTCP models for patient-rated xerostomia and sticky saliva among patients treated with intensity modulated radiotherapy. *Radiother Oncol*. 2012;105:94–100.

10. Beetz I, Schilstra C, Burlage FR, Koken PW, Doornaert P, Bijl HP, Chouvalova O, Leemans CR, de Bock GH, Christianen ME, van der Laan BF, Vissink A, Steenbakkers RJ, Langendijk JA. Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: the role of dosimetric and clinical factors. *Radiother Oncol*. 2012;105:86–93.

11. Lee TF, Chao PJ, Wang HY, Hsu HC, Chang P, Chen WC. Normal tissue complication probability model parameter estimation for xerostomia in head and neck cancer patients based on scintigraphy and quality of life assessments. *BMC Cancer*. 2012;12:567.

12. Lee TF, Fang FM. Quantitative analysis of normal tissue effects in the clinic (QUANTEC) guideline validation using quality of life questionnaire datasets for parotid gland constraints to avoid causing xerostomia during head-and-neck radiotherapy. *Radiother Oncol*. 2013;106:352–8.

13. Lee TF, Chao PJ, Ting HM, Chang L, Huang YJ, Wu JM, Wang HY, Horng MF, Chang CM, Lan JH, Huang YY, Fang FM, Leung SW. Using multivariate regression model with least absolute shrinkage and selection operator (LASSO) to predict the incidence of Xerostomia after intensity-modulated radiotherapy for head and neck cancer. *PLoS One*. 2014;9:e89700.

14. Jellema AP, Doornaert P, Slotman BJ, Leemans CR, Langendijk JA. Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy? *Radiother Oncol*. 2005;77:164–71.

15. Christianen ME, Schilstra C, Beetz I, Muijs CT, Chouvalova O, Burlage FR, Doornaert P, Koken PW, Leemans CR, Rinkel RN, de Bruijn MJ, de Bock GH, Roodenburg JL, van der Laan BF, Slotman BJ, Verdonck-de Leeuw IM, Bijl HP, Langendijk JA. Predictive modelling for swallowing dysfunction after primary (chemo)radiation: results of a prospective observational study. *Radiother Oncol*. 2012;105:107–14.

16. Christianen ME, van der Schaaf A, van der Laan HP, Verdonck-de Leeuw IM, Doornaert P, Chouvalova O, Steenbakkers RJ, Leemans CR, Oosting SF, van der Laan BF, Roodenburg JL, Slotman BJ, Bijl HP, Langendijk JA. Swallowing sparing intensity modulated radiotherapy (SW-IMRT) in head and neck cancer: clinical validation according to the model-based approach. *Radiother Oncol*. 2016;118:298–303.

17. Blanchard P, Garden AS, Gunn GB, Rosenthal DI, Morrison WH, Hernandez M, Crutison J, Lee JJ, Ye R, Fuller CD, Mohamed AS, Hutcheson KA, Holliday EB, Thaker NG, Sturgis EM, Kies MS, Zhu XR, Mohan R, Frank SJ. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer: a case matched analysis. *Radiother Oncol*. 2016;118:298–303.

18. Dirix P, Abbeel S, Vanstraalen B, Hermans R, Nuyts S. Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures. *Int J Radiat Oncol Biol Phys*. 2009;75:385–92.

19. Mazzola R, Ricchetti F, Fiorentina A, Fersino S, Giay Leva N, Naccarato S, Sicignano G, Albanese S, Di Paola G, Alterio D, Ruggiari R, Alongi F. Dose-volume-related dysphagia after constrictor mucles definition in head and neck cancer intensity-modulated radiation treatment. *Br J Radiol*. 2014;87(1044).

20. Christianen ME, Langendijk JA, Westerlaan HE, van de Water TA, Bijl HP. Delineation of organs at risk involved in swallowing for radiotherapy treatment planning. *Radiother Oncol*. 2011;101:394–402.
21. Caudell JJ, Schaner PE, Desmond RA, Meredith RF, Spencer SA, Bonner JA. Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys*. 2010;76:403–9.

22. Sanguineti G, Gunn GB, Parker BC, Endres EJ, Zeng J, Fiorino C. Weekly dose-volume parameters of mucosa and constrictor muscles predict the use of percutaneous endoscopic gastrostomy during exclusive intensity-modulated radiotherapy for oropharyngeal cancer. *Int J Radiat Oncol Biol Phys*. 2011;79:52–9.

23. Wopken K, Bijl HP, van der Schaaf A, van der Laan BF, Roosenburg JL, Leemans CR, Verdonck-de Leeuw IM, Langendijk JA. Development of a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence after curative radiotherapy/chemo-radiotherapy in head and neck cancer. *Radiother Oncol*. 2014;113:95–101.

24. Vlacich G, Spratt DE, Diaz R, Phillips JG, Crass J, Li CI, Shyr Y, Cmelak AJ. Dose to the inferior pharyngeal constrictor predicts prolonged gastrostomy tube dependence with concurrent intensity-modulated radiation therapy and chemotherapy for locally-advanced head and neck cancer. *Radiother Oncol*. 2014;110:435–40.

25. Li B, Li D, Lau DH, Farwell DG, Luu Q, Rocke DM, Newman K, Courquin J, Purdy JA, Chen AM. Clinical-dosimetric analysis of measures of dysphagia including gastrostomy-tube dependence among head and neck cancer patients treated definitively by intensity-modulated radiotherapy with concurrent chemotherapy. *Radiother Oncol*. 2009;4:52.

26. Vergouwe Y, Nieboer D, Oostenbrink R, Debray TPA, Murray GD, Kattan MW, Koffijberg H, Moons KGM, Steyerberg EW. A closed testing procedure to select an appropriate method for updating prediction models. *Stat Med*. 2017;36:4529–39.

27. Kumar R, Madanikia S, Starmer H, Yang W, Murano E, Alcorn S, McNutt T, Le Y, Quon H. Radiation dose to the floor of mouth muscles predicts swallowing complications following chemoradiation in oropharyngeal squamous cell carcinoma. *Oral Oncol*. 2014;50:65–70.

28. Brouwer CL, Steenbakkers RJ, Bourhis J, Budach W, Grau C, Grégoire V, van Herk M, Lee A, Maingon P, Nutting C, O’Sullivan B, Porceddu SV, Rosenthal DI, Šijtsema NM, Langendijk JA. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. *Radiother Oncol*. 2015;117:83–90.

29. Van den Bosch L, Schuit E, van der Laan HP, Reitsma JB, Moons KGM, Steenbakkers RJHM, Hoebers FJP, Langendijk JA, van der Schaaf A. Key challenges in normal tissue complication probability model development and validation: towards a comprehensive strategy. *Radiother Oncol*. 2020;148:151–6.

30. Schwartz DL, Hutcheson K, Barringer D, Tucker SL, Kies M, Holsinger FC, Ang KK, Morrison WH, Rosenthal DI, Garden AS, Dong L, Lewin JS. Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. *Int J Radiat Oncol Biol Phys*. 2010;78:1356–65.

31. Dean JA, Welsh LC, Wong KH, Aleksic A, Dunne E, Islam MR, Patel A, Patel P, Petkar I, Phillips I, Sham J, Schick U, Newbold KL, Bhide SA, Harrington KJ, Nutting CM, Gulliford SL. Normal tissue complication probability (NTCP) modelling of severe acute mucositis using a novel oral mucosal surface organ at risk. *Clin Oncol (R Coll Radiol)*. 2017;29:263–73.

32. Dean JA, Wong KH, Welsh LC, Jones AB, Schick U, Newbold KL, Bhide SA, Harrington KJ, Nutting CM, Gulliford SL. Normal tissue complication probability (NTCP) modelling using spatial dose metrics and machine learning methods for severe acute oral mucositis resulting from head and neck radiotherapy. *Radiother Oncol*. 2016;120:21–7.

33. Lee TF, Liou MH, Ting HM, Chang L, Lee HY, Wan Leung S, Huang CJ, Chao PJ. Patient- and therapy-related factors associated with the incidence of xerostomia in nasopharyngeal carcinoma patients receiving parotid-sparing helical tomotherapy. *Sci Rep*. 2015;5:13165.

34. Strigari L, Pedicini P, D’Andrea M, Pinnarò P, Marucci L, Giordano C, Benassi M. A new model for predicting acute mucosal toxicity in head-and-neck cancer patients undergoing radiotherapy with altered schedules. *Int J Radiat Oncol Biol Phys*. 2012;83:e697–702.

35. Sapir E, Tao Y, Fung F, Samuels S, El Naqa I, Murdoch-Kinch CA, Feng M, Schipper M, Eisbruch A. Predictors of dysgeusia in patients with oropharyngeal cancer treated with chemotherapy and intensity modulated radiation therapy. *Int J Radiat Oncol Biol Phys*. 2016;96:354–61.